OCX OncoCyte Inc: Earnings per share for the last twelve months

Public company logo of OncoCyte Corp. (OCX)

Geopolitical fragmentation and sanctions have restricted data exchange and reagent supplies, which impacted the peak of year-over-year EPS growth dynamics over the rolling period. OncoCyte Corporation (OCX) currently relies on the uniqueness of DetermaRx tests for the early detection of lung cancer recurrence. A strategic pivot has concentrated resources on scaling high-margin diagnostics, and -60.00 captures the current state of the parameter.

OncoCyte (OCX): Earnings per share for the last twelve months from 02/11/2024 to 02/20/2024

OCX (oncocyte.com): analytical breakdowns and indicator data

- current quotes and average value forecast:
Initial company analysis:OCX, OncoCyte Corp
Original product of OncoCyte Corporation

OncoCyte Corporation (OCX) generates revenue through high-tech biomarker diagnostics for lung cancer therapy. This metric measures the percentage change in net income per share over a rolling year. Investors assess the pace of business scaling, separating real growth from temporary profit fluctuations. A steady ascent confirms the effectiveness of test commercialization. By analyzing this EPS TTM annual trend chart, one can determine the risk of a rapid asset devaluation.